ESMO 2022

Endocrine response in eBC

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Roadmap for the adjuvant setting

QoL and longterm toxicity

Long-term data on dose density therapy in chemotherapy

Consolidating data from prospective studies

DD is the champion!

My highlights of ESMO22

Dose dense is better

Dose-dense standard of care is the optimal care

Immuntherapy only for low risk patients?

Simple and cheap surgical technique may impact survival in early breast cancer

Dose-dense therapy is beneficial for all patients

Reduction of peripheral neuropathy with taxane therapy

Schéma dose-dense bénéfique pour toutes les patientes

Il vincitore e’ il dose dense!!

Datele trialurilor se consolideata

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

I miei punti salienti di ESMO22

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Status update - adjuvant IO. Are TILs prognostic?

Unmeet needs and my wishes for 2022!

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

How to deal with the negative SERD data?

Tailoring Adjuvant Therapy

My highlights of ESMO22

Update on biomarkers on ADCs of the DAISY trial

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Another option for heavily pre-treated HR+ advanced breast cancer patients

CDK4/6i could be an option for selected ER+/HER2+ disease

Survival benefit from SG in mBC

Exciting data, but Phase 3 studies are needed

TROPiCS-02 highlights

The third in the bunch

New treatment option for heavily pre-treated patients with ER+ MBC

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

Discontinued development

Survival benefit in endocrine sensitive patients

More therapy options for patients with HR+, HER2+ disease

ADC after ADC - is there any orientation?

Sacituzumab govitecan for everybody!

VEX has no place in chemotherapy of metastatic breast cancer

SG is a novel treatment option for HR+/HER2- disease

OS not significant, but re-assuring new data

Negative and yet positive?!

Interim analysis shows promising data on Abema in the 1st Line

HER2+ and still without chemotherapy

TROPiCS-02 highlights

Sacituzumab Govitecan: Un farmaco per tutte?

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Survie globale pas encore significative statistiquement mais données rassurantes

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

I miei punti salienti di ESMO22

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Nouvelles données des analyses expolratoires dans l’étude DAISY

Sopravvivenza globale nello studio MONARCH3

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

ADAURA Update - preventing relapse or just delaying it?

Osimertinib stays standard adjuvant

Long term follow-up of ADAURA trial

Concurrent preoperative IO/CRT in early lung cancer

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Is OS really needed?

Osimertinib - curing or delaying relapse?

INCREASE - to good to be true?

Pollution and lung cancer - one mechanism revealed

ADAURA revisited

Window for treatment selection

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Neoadjuvant strategies for PD-L1 < 1 %

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Pollution et cancer du poumon - un mécanisme mis en évidence

ADAURA revisited

Osimertinib bleibt Standard adjuvant

Osimertinib: una cura o ritarda la ripresa di malattia?

Langzeitdaten ADAURA

Eine Plattform für "take the winner"-Strategie

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Important data on borderline resectable patients

DFS matters!

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Can IO be discontinued?

Sotorasib vs. Docetaxel in mKRAS G12C

Sotorasib: sweet and sour results

Is shorter immunotherapy equally effective and less physically demanding?

One more brick in the KRAS G12C wall

Emerging IO mono options in the first line

HER2 - the next actionable mutation in lung cancer?

Sotorasib - a new standard of care?

DESTINY-Lung02 - better than the original?

Cemiplimab beyond progression?

The journey at KRAS G12C continues

Preview on lung cancer highlights

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Immunotherapy in unfit population? Perhaps...

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Chemoimmunotherapy - improvement of survival after 5 years

A new step in treatment of KRAS G12C mutant NSCLC

Can we finally treat poor prognostic patients with immunotherapy?

Atezolizumab better than vinorelbin in reduced performance status

5 years of chemoimmunotherapy: solid grounded

If you don't look, vou don't find - once you found it, you'll treat it!

Liquid biopsy monitoring in treatment decisions

Pneumonitis and T-DXd

Real-world data on Atezolizumab

New therapy combination after progression on 1L osimertinib

Question about timing and duration of immunotherapy still unanswered

Induction chemoimmunotherapy in borderline resectability?

5-year update on 1st line chemoimmunotherapy

5-year data on survival under immunotherapy

Poseidon and STK11/KEAP

IO-IO neoadjuvant bei PD-L1 neg.

5 Jahre Chemo-Immuntherapie: starker Effekt

Sotorasib vs. Docetaxel bei mKRAS G12C

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Neue Therapiekombination in der Resistenz nach Osimertinib

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Atezo besser als Vino bei PS2-3

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Resultados Agridulces de Sotorasib

Un mattone in piu' nel muro del KRAS G12C

Kann IO pausiert werden?

Chimio-immunothérapie - amélioration de la survie après 5 ans

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Poseidon und STK11/KEAP

Les études incontournables à l’ESMO 2022

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Cemiplimab beyond progression?

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Données de vie réelle avec l’atezolizumab

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Liquid Biopsy Monitoring zur Therapiesteuerung

Immunoterapia nella popolazione non fit: forse

5-Jahresüberleben mit Immuntherapie

Die Reise bei KRAS G12C geht weiter

Neue Option der IO-Therapie in der Erstlinie

Pneumonitis und T-DXd

New strategies in immunotherapy

A positive study! With a question mark?

Heterogenity in the genetic landscape - little progress in molecular alterations

Novel data and long-term efficacy of chemo-IO in mNSCLC

Two negative studies question adjuvant approach in RCC

New combo - triplet therapy for kidney cancer

Immune-based peri-operative treatment in RCC: What went wrong?

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Exciting data for high-risk patients: is this the start of a new era?

Adjuvant Immuntherapy in kidney cancer

More questions being raised

No value of IPI/Nivo in the adjuvant setting.

Place of triplet therapy

News in terms of adjuvant

Brief highlights about RCC & urothelial cancer from ESMO22

Terapia triple para cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Inmunoterapia adyuvante en el cancer renales

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Shedding light on TKI/Checkpointinhibitor combinations

Immunomodulation in combination with checkpointinhibiton

Therapy combinations in RCC - what is the role of triplet therapy?

Brief highlights about RCC & urothelial cancer from ESMO22

EV + pembrolizumab in cisplatin-ineligible patients

EV + Pembro with excellent response rates

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Promising data, but beware of toxicity

Optimizing cabazitaxel chemotherapy

Length of hormone therapy after radiation

QoL data from ARASENS triplet therapy study mHRPC

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Cabazitaxel better tolerated in elderly men

In older vulnerable - less is more

Biomarker data for better patients selection

Combination of olaparib leads to promising results

Further evaluation of PSA correlates

Radicals - ADT & Radiotherapy

ADCs - a possible therapeutic approach

Triplet therapy with darolutamide in prostate cancer

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

ADT + ENZA better choice than monotherapy

PSA at 8-months as a biomarker

IO + PARP without benefit in the allcomer situation

Update on the PROpel study

Genetic testing before PARP therapy is useful

PSA efter 8 månader i PEACE-1 studien som biomarkör

Uppdatering i PROpel studien

Livskvalitetsuppföljning i ARASENS studien

Intimate partner violence in cancer patients

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

New group of substances for rare diseases

Novel approach von Biontech towards Cancer – game changing potential?!

Addition of CPI to Radiochemotherapy in LA-HNSCC?

TILs - Fashion is the eternal return of the old